Feb 08 2021 - Feb 11 2021
WORLDSymposium
San Diego, CA, USA
Press releases
Eleva’s drug candidate to be examined for use in Covid-19 treatment
Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.
Eleva secures up to EUR 60 million to advance a drug candidate, appoints new board member
Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.
Greenovation transforms into Eleva
Greenovation is launching its supreme moss-based development platform with a new business model and is transforming into a new company, Eleva.
